New pill for tough tumors enters human testing

NCT ID NCT04192344

First seen Mar 22, 2026 · Last updated Jun 19, 2026 · Updated 15 times

Summary

This early-stage study tests an experimental pill called ABSK021 in people with advanced solid tumors (including a rare joint tumor called TGCT) who have run out of standard options. The main goal is to check safety and find the best dose, while also seeing if the drug can shrink tumors. About 276 participants will take the drug by mouth and be closely monitored.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Jishuitan Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

    Contact

    Contact

  • Hebei Medical University Third Hospital

    COMPLETED

    Shijiazhuang, Hebei, China

  • Henan Cancer Hospital

    ACTIVE_NOT_RECRUITING

    Zhengzhou, Henan, China

  • Huashan Hospital of Fudan University

    COMPLETED

    Shanghai, Shanghai Municipality, China

  • Jiangsu Province Hospital

    ACTIVE_NOT_RECRUITING

    Nanjing, Jiangsu, China

  • Liaoning Cancer Hospital

    COMPLETED

    Shenyang, Liaoning, China

  • MD Anderson Cancer Center

    COMPLETED

    Houston, Texas, 77030, United States

  • Nanjing Drum Tower Hospital

    ACTIVE_NOT_RECRUITING

    Nanjing, Jiangsu, China

  • Precision NextGen Oncology

    ACTIVE_NOT_RECRUITING

    Beverly Hills, California, 90212, United States

  • SCRI at HealthOne

    COMPLETED

    Denver, Colorado, 80218-1238, United States

  • Shanghai Sixth People's Hospital

    COMPLETED

    Shanghai, Shanghai Municipality, China

  • The First Affiliated Hospital of Sun Yat-sen University

    RECRUITING

    Guangdong, Guangzhou, China

    Contact

    Contact

  • The First Affiliated Hospital of Zhengzhou Universtity

    COMPLETED

    Zhengzhou, Henan, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, China

    Contact

    Contact

  • The Winship Cancer Institute of Emory University

    COMPLETED

    Atlanta, Georgia, 30322, United States

  • West China Hospital of Sichuan University

    RECRUITING

    Chengdu, Sichuan, China

    Contact

    Contact

  • Xi'an Hong Hui Hospital

    RECRUITING

    Xian, Shanxi, China

    Contact

    Contact

Conditions

The condition(s) this trial relates to.

Giant Cell Tumor of Tendon Sheath neoplasm tenosynovial giant cell tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.